Claims
- 1. A method for treating a condition selected from the group: acute coronary ischemic syndrome, thrombosis, thromboembolism, thrombic occlusion and reclusion, restenosis, transient ischemic attack, and first or subsequent thrombotic stroke comprising administration of a sub-therapeutic dose of a low molecular weight heparin and a sub-therapeutic dose of a platelet GPIIb/IIIa antagonist to a mammal in need of such treatment.
- 2. A method according to claim 1, wherein the platelet GPIIb/IIIa antagonist is roxifiban.
- 3. A method according to claim 1, wherein the low molecular weight heparin is tinzaparin.
- 4. A method according to claim 1, wherein the administration is subcutaneous.
- 5. A pharmaceutical composition comprising a platelet GPIIb/IIIa antagonist and a low molecular weight heparin and a pharmaceutically acceptable carrier.
- 6. A pharmaceutical composition according to claim 5, wherein the platelet GPIIb/IIIa antagonist is roxifiban.
- 7. A pharmaceutical composition according to claim 5, wherein the low molecular weight heparin is tinzaparin.
- 8. A kit comprising a platelet GPIIb/IIIa antagonist and a low molecular weight heparin for subcutaneous injection.
- 9. A method of treating thrombosis in a mammal comprising administering to said mammal a combination of: (i) a subtherapeutic dose of GPIIb/IIIa antagonist selected from the group consisting of abciximab, eptifibatide, tirofiban, lamifiban, lefradafiban, sibrafiban, orbofiban, xemilofiban, a compound of the formula (A):
- 10. The method of claim 9 wherein the combination of (i) and (ii) or (iii) provides a synergistic effect.
- 11. The method of claim 9, wherein the combination administered is a combination of the GPIIb/IIIa antagonist and a low molecular weight heparin.
- 12. The method of claim 11, wherein the GPIIb/IIIa antagonist is administered in a subtherapeutic amount.
- 13. The method of claim 11, wherein the GPIIb/IIIa antagonist is compound A or compound B.
- 14. The method of claim 11, wherein the low molecular weight heparin is dalteparin (fragmin).
- 15. The method of claim 11, wherein the GPIIb/IIIa antagonist is compound A or compound B and the low molecular weight heparin is dalteparin (fragmin).
- 16. The use of a combination of: (i) a subtherapeutic dose of GPIIb/IIIa antagonist selected from the group consisting of abciximab, eptifibatide, tirofiban, lamifiban, lefradafiban, sibrafiban, orbofiban, xemilofiban, a compound of the formula (A):
- 17. A method of treating thrombosis in a mammal comprising administering to said mammal (i) tissue plasminogen activator and (ii) a compound of the formula:
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional Application No. 60/123,820, filed Mar. 11, 1999.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60123820 |
Mar 1999 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09523395 |
Mar 2000 |
US |
Child |
10003972 |
Nov 2001 |
US |